Pulmonary drug delivery company Vectura released encouraging results after a transformational year, with revenues ahead of expectations thanks to growing royalty income.The Wiltshire company reached positive earnings before interest, tax, depreciation and amortisation (EBITDA) of £5.2m in the year to March, versus a loss at this level of £3.4m a year before. Turnover, at £36.5m, beat forecasts due to royalties and development services revenue slightly ahead of expectations, with adjusted losses before tax of £4.8m. Cash and cash equivalents stood at £81.7m at the period end.Chief Executive Dr Chris Blackwell hailed a "very significant" year, driven by the progress made from the approvals and commercialisation of partnered assets. Seebri Breezhaler, partnering with Novartis, gained approved in over 60 countries, including EU, Japan, Canada and Australia, with net sales of $82m. The Ultibro Breezhaler, also with Novartis, has launched in seven countries to date and been approved in over 30, including EU, Japan, Canada and Australia.Looking ahead, Blackwell said he anticipates the continued commercialisation of Seebri, Ultibro and AirFluSal Forspiro to augment growing royalty streams. He highlighted the recent acquisition of Activaero, which broker N+1 Singer said would open up the opportunity to leverage Vectura's formulation expertise in a proprietary inhalation solution.The approvals of GlaxoSmithKline's fixed-dose combinations BREO and ELLIPTA generated first royalties during year and are expected to generate material royalties to Vectura for the next few years.Shares in Vectura were up 1.27% to 129.13p at 12.30 on Wednesday.OH